MedTrace Logo

PDL1 in Ovarian High Grade Serous Carcinoma

NCT04507191 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2020-08-11

No results posted yet for this study

Summary

the main purpose is to study the prognostic effect of PDL1 in ovarian cancer especially HGSC. Therefore, in the present study the investigators analyzed the expression of PDL1in HGSC by immunohistochemistry, and results were correlated to prognosis.

Conditions

Interventions

DIAGNOSTIC_TEST

immunohistochemical staining

immunohistochemical staining of programmed death-ligand 1 (PDL1) marker

Sponsors & Collaborators

  • Mansoura University Hospital

    collaborator OTHER

  • Port Said University hospital

    lead OTHER

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-01
Primary Completion
2019-12-01
Completion
2019-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04507191 on ClinicalTrials.gov